Human medicines European public assessment report (EPAR): Wakix, pitolisant, Narcolepsy, Date of authorisation: 31/03/2016, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Wakix, pitolisant, Narcolepsy, Date of authorisation: 31/03/2016, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Gazyvaro, obinutuzumab, Leukemia, Lymphocytic, Chronic, B-Cell, Date of authorisation: 22/07/2014, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Gazyvaro, obinutuzumab, Leukemia, Lymphocytic, Chronic, B-Cell, Date of authorisation: 22/07/2014, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Tyruko, natalizumab, Multiple Sclerosis, Relapsing-Remitting;Multiple Sclerosis, Date of authorisation: 22/09/2023, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Tyruko, natalizumab, Multiple Sclerosis, Relapsing-Remitting;Multiple Sclerosis, Date of authorisation: 22/09/2023, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Mylotarg, gemtuzumab ozogamicin, Leukemia, Myeloid, Acute, Date of authorisation: 19/04/2018, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Mylotarg, gemtuzumab ozogamicin, Leukemia, Myeloid, Acute, Date of authorisation: 19/04/2018, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Kauliv, teriparatide, Osteoporosis;Osteoporosis, Postmenopausal, Date of authorisation: 12/01/2023, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Kauliv, teriparatide, Osteoporosis;Osteoporosis, Postmenopausal, Date of authorisation: 12/01/2023, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Enbrel, etanercept, Spondylitis, Ankylosing;Arthritis, Juvenile Rheumatoid;Arthritis, Psoriatic;Psoriasis;Arthritis, Rheumatoid, Date of authorisation: 02/02/2000, Revision: 72, Status: Authorised

Human medicines European public assessment report (EPAR): Enbrel, etanercept, Spondylitis, Ankylosing;Arthritis, Juvenile Rheumatoid;Arthritis, Psoriatic;Psoriasis;Arthritis, Rheumatoid, Date of authorisation: 02/02/2000, Revision: 72, Status: Authorised

Human medicines European public assessment report (EPAR): Lumykras, sotorasib, Carcinoma, Non-Small-Cell Lung, Date of authorisation: 06/01/2022, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Lumykras, sotorasib, Carcinoma, Non-Small-Cell Lung, Date of authorisation: 06/01/2022, Revision: 2, Status: Authorised

Committee for Medicinal Products for Veterinary Use (CVMP): 3-5 October 2023, European Medicines Agency, Amsterdam, the Netherlands, from 03/10/2023 to 05/10/2023

Committee for Medicinal Products for Veterinary Use (CVMP): 3-5 October 2023, European Medicines Agency, Amsterdam, the Netherlands, from 03/10/2023 to 05/10/2023

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness